See original article:

Download PDFPDF

Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Pleiotropism of statins includes adverse effects

    Dear Editor,

    The authors of the editorial discuss the molecular basis of the pleiotropic positive effects of statins, but they fail to mention that the same molecular events are very likely to be responsible for the adverse effects like myopathy, rhabdomyolysis and neuropathy. For example, the authors describe the possible anti-oxidative properties of statins, but as inhibitors of cholesterol biosynthesis statins a...

    Show More
    Conflict of Interest:
    None declared.